- Home
- IVCA vs ASMB Comparison
IVCA vs ASMB Comparison
Compare IVCA & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVCA
- ASMB
- Stock Information
- Founded
- IVCA 2021
- ASMB 2005
- Country
- IVCA Cayman Islands
- ASMB United States
- Employees
- IVCA N/A
- ASMB N/A
- Industry
- IVCA Blank Checks
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- IVCA Finance
- ASMB Health Care
- Exchange
- IVCA Nasdaq
- ASMB Nasdaq
- Market Cap
- IVCA 92.4M
- ASMB 106.5M
- IPO Year
- IVCA 2022
- ASMB 2010
- Fundamental
- Price
- IVCA $11.68
- ASMB $16.26
- Analyst Decision
- IVCA
- ASMB Buy
- Analyst Count
- IVCA 0
- ASMB 2
- Target Price
- IVCA N/A
- ASMB $35.00
- AVG Volume (30 Days)
- IVCA 358.0
- ASMB 24.9K
- Earning Date
- IVCA 01-01-0001
- ASMB 11-07-2024
- Dividend Yield
- IVCA N/A
- ASMB N/A
- EPS Growth
- IVCA N/A
- ASMB N/A
- EPS
- IVCA 0.29
- ASMB N/A
- Revenue
- IVCA N/A
- ASMB $28,326,000.00
- Revenue This Year
- IVCA N/A
- ASMB $267.67
- Revenue Next Year
- IVCA N/A
- ASMB $46.15
- P/E Ratio
- IVCA $40.19
- ASMB N/A
- Revenue Growth
- IVCA N/A
- ASMB N/A
- 52 Week Low
- IVCA $10.88
- ASMB $7.68
- 52 Week High
- IVCA $12.37
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- IVCA 80.56
- ASMB 45.99
- Support Level
- IVCA $11.44
- ASMB $15.92
- Resistance Level
- IVCA $11.50
- ASMB $17.48
- Average True Range (ATR)
- IVCA 0.00
- ASMB 0.99
- MACD
- IVCA 0.00
- ASMB -0.08
- Stochastic Oscillator
- IVCA 100.00
- ASMB 16.35
About IVCA Investcorp India Acquisition Corp.
Investcorp India Acquisition Corp is a newly organized blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.